Persistent high on-treatment platelet reactivity in acute coronary syndrome
Tóm tắt
Persistent high on-treatment platelet reactivity in acute coronary syndrome (ACS) patients managed with appropriate antiplatelet therapy has been correlated with increased risk of cardiovascular events; however, the evolution of this phenomenon overtime is not well known. We investigated platelet activity at a three month follow-up after initial presentation with an ACS. We enrolled a total of 124 patients in the study, 65 were diagnosed with ACS and 59 controls who presented with non-cardiac chest pain for baseline comparisons. Of the enrolled patients, we had 25 ACS patients return, in stable condition, three months after their initial presentation for repeat platelet functional testing. Epinephrine (EPI), adenosine diphosphate (ADP), and arachidonic acid induced platelet aggregation were monitored at baseline with repeat measurement of EPI- and ADP-stimulated aggregation at follow-up. In addition, P-selectin and PAC-1 expression were monitored at presentation and at a three month follow-up period. ACS patients were maintained on aspirin therapy during the intervening period. At the three month follow-up visit, ACS patients initiated on aspirin had no significant percentage change in aggregation to submaximal concentrations of EPI and ADP. They also had no significant percentage change in PAC-1 or P-selectin expression. This study demonstrates persistent high on-treatment platelet reactivity in ACS patients at a three month follow-up, which may place these patients at increased risk of recurrent cardiovascular events.
Tài liệu tham khảo
Kottke-Marchant K (2009) Importance of platelets and platelet response in acute coronary syndromes. Cleve Clin J Med 76(Suppl 1):S2–S7
Sofi F, Marcucci R, Gori AM, Abbate R, Gensini GF (2008) Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events–a meta-analysis. Int J Cardiol 128(2):166–171
Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV (2007) Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167(15):1593–1599
Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF (2010) High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 104(2):279–286
Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56(12):919–933
Edlund A, Berglund B, van Dorne D, Kaijser L, Nowak J, Patrono C, Sollevi A, Wennmalm A (1985) Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation. Circulation 71(6):1113–1120
Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD (1994) Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25(12):2331–2336
Muir AR, McMullin MF, Patterson C, McKeown PP (2009) Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 95(15):1225–1229
Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F (2004) Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 43(6):979–984
Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, Davi G, Patrono C (2009) Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol 53(8):667–677
Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD (2009) Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 120(25):2586–2596
Williams MS, Kickler TS, Vaidya D, Ng’alla LS, Bush DE (2006) Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis 21(3):241–247
Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF (2005) Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 106(8):2723–2729
Christie DJ, Kottke-Marchant K, Gorman RT (2008) Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 19(2):104–110
Kempfert J, Anger K, Rastan A, Krabbes S, Lehmann S, Garbade J, Sauer M, Walther T, Dhein S, Mohr FW (2009) Postoperative development of aspirin resistance following coronary artery bypass. Eur J Clin Invest 39(9):769–774
Kennon S, Price CP, Mills PG, Macey M, Cooper J, Clarke H, Timmis AD (2003) The central role of platelet activation in determining the severity of acute coronary syndromes. Heart 89(10):1253–1254
Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabate M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R (2009) Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 119(25):3215–3222
Patti G, Fossati C, Manzoli A, D’Ambrosio A, Abbate A, Montesanti R, Di Sciascio G (2000) Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease. Clin Ter 151(4):301–306
Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57(25):2474–2483
Wagner DD (2005) New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 25(7):1321–1324
Gurbel PA, Kereiakes DJ, Serebruany VL (2000) Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study group. J Thromb Thrombolysis 10(1):15–22
Cheng G, Shan J, Xu G, Liu P, Zhou Y, Zhu Y, Lu X (2007) Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease. J Clin Pharm Ther 32(3):287–292
Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41(6):961–965
Atiemo AD, Ng’Alla LS, Vaidya D, Williams MS (2008) Abnormal PFA-100 closure time is associated with increased platelet aggregation in patients presenting with chest pain. J Thromb Thrombolysis 25(2):173–178